Elsevier

The Lancet Oncology

Volume 13, Issue 8, August 2012, Pages 744-745
The Lancet Oncology

Comment
The coming of age of MEK

https://doi.org/10.1016/S1470-2045(12)70317-0Get rights and content

References (11)

There are more references available in the full text version of this article.

Cited by (6)

  • Dysregulation of RNA polymerase I transcription during disease

    2013, Biochimica et Biophysica Acta - Gene Regulatory Mechanisms
    Citation Excerpt :

    In some cases, signaling down the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR cascades converge to regulate Pol I transcription leading to cancer. The HER2 and EGF receptors themselves are also subject to amplification and activating mutation in cancer [190,195,197,203]. The overactivity of these receptors can “hyperactivate” the RAS and PI3K pathways resulting in the stimulation of rDNA transcription.

  • Novel drugs against non-small-cell lung cancer

    2014, Current Opinion in Oncology
View full text